<DOC>
	<DOCNO>NCT00685711</DOCNO>
	<brief_summary>Cat allergy increasingly prevalent condition , affect 10-15 % patient allergic rhinoconjunctivitis and/or asthma . Cat-PAD novel , synthetic , allergen-derived peptide desensitise vaccine , currently develop treatment cat allergy . This study investigate safety Cat-PAD administer increase single dos .</brief_summary>
	<brief_title>Safety Cat-PAD Cat Allergic Subjects</brief_title>
	<detailed_description>This study design two centre , randomise , placebo-controlled , escalate single dose study 88 cat allergic subject . Cohorts 8 subject enrol . Each cohort undergo screen 14-28 day treatment baseline challenge EPSR LPSR cat allergen inject arm 7 day treatment . On treatment day , subject inject either intradermally ( skin ) subcutaneously ( skin ) single dose Cat-PAD placebo safety observation make 8 h. After 21 day , subject cat allergen inject arm EPSR LPSR record . The dose Cat-PAD increase successive cohort , provide previous dose test well tolerate .</detailed_description>
	<criteria>A reliable history rhinoconjunctivitis ( sneeze , rhinorrhoea , nasal blockage , itchy/red/sore/watering eye ) control asthma ( GINA ( 2006 ) classification 1 ) exposure cat least 1 year . LatePhase Allergic Skin Reaction ( LPSR ) 0.010 HEP unit Leti cat allergen eight hour intradermal injection great 25mm diameter response single arm . Subjects asthma fall GINA ( 2006 ) classification 2 ( partly control ) 3 ( uncontrolled ) . A history anaphylaxis cat allergen . Subjects cat specific IgE &gt; 100 kU/L . Subjects FEV1 &lt; 80 % normal . Subjects acute phase skin response cat allergen weal diameter &gt; 30mm . Subjects suffer hay fever , complete clinical study outside pollen season . Allergen immunotherapy last 5 year Cat Dander immunotherapy ever . Use follow therapy period specify prior screen visit make subject ineligible study : corticosteroid : ( depot : 90 day ; systemic : 30 day ; dermatological , intranasal , inhalational : 15 day ) ; cromones ( 14 day ) ; antihistamine loratadine ( nasal longacting oral : 10 day ; shortacting oral , ocular : 7 day ) ; leukotriene inhibitor ( 10 day ) ; anticholinergic ( 7 day ) ; alphaadrenergic agonist ( 7 day ) ; tricyclic antidepressant ( 14 day ) . If becomes medical necessity subject use one contraindicate medication study become individual stopping criterion . Subjects administration adrenaline contraindicate ( e.g . subject acute chronic symptomatic coronary heart disease severe hypertension ) . Subjects treat betablockers</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Cat allergy</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Cat-PAD</keyword>
</DOC>